Seasonal Allergic Rhinitis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide Used Four Times a Day in the Symptomatic Treatment of Seasonal Allergic Rhinitis
The purpose of this study is to evaluate the effect of four times a day treatment with nasal carbon dioxide in patients with Seasonal Allergic Rhinitis symptoms.
This randomized, double-blind, placebo-controlled, multi-center, parallel group, pilot study
will evaluate the efficacy and safety of a four times a day treatment with nasal,
non-inhaled administration of CO2 (nasal CO2) in patients with SAR. Approximately 50
patients who meet the eligibility criteria will be enrolled into this study at up to 4 sites
to ensure that approximately 30 patients complete the study.
Patients will be randomized to one of two treatment groups and be provided with either an
active or placebo dispenser.
All patients will administer study drug for 10 seconds to each nostril once on Day 0 in the
clinic then four times a day during waking hours (approximately 4 hours apart) for 14 days.
Patients will assess their nasal and non-nasal symptoms in a patient diary. Each patients
participation in the study may last up to 72 days.
There will be a total of 5 scheduled clinic visits:
- Visit 1 Screening
- Visit 2 Enrollment (within 42 days of Visit 1)
- Visit 3 Randomization (after the completion of a 3-7 day run-in period)
- Visit 4 Mid-Treatment (Day 7 ± 1 day)
- Visit 5 End of Treatment (within 1-3 days of last study drug administration) Sites will
follow-up with randomized patients via telephone 7 ± 1 days after the last study drug
administration.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01337323 -
Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting
|
N/A | |
Completed |
NCT01171664 -
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects
|
Phase 2 | |
Completed |
NCT00784732 -
A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber
|
Phase 2 | |
Completed |
NCT00619827 -
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
|
Phase 1 | |
Completed |
NCT00578929 -
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
|
Phase 3 | |
Completed |
NCT00209365 -
The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit
|
N/A | |
Terminated |
NCT00223587 -
Seasonal Allergic Rhinitis and Driving Ability
|
Phase 4 | |
Completed |
NCT00637455 -
Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel
|
Phase 4 | |
Completed |
NCT00963599 -
Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)
|
Phase 3 | |
Recruiting |
NCT05346718 -
Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis
|
N/A | |
Completed |
NCT06126952 -
Azelastine Allergen Chamber - Onset of Action Study
|
Phase 2 | |
Completed |
NCT02245360 -
Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis
|
Phase 3 | |
Completed |
NCT01940146 -
Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
|
Phase 2 | |
Completed |
NCT01230619 -
Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis
|
Phase 2 | |
Completed |
NCT00561717 -
A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis
|
Phase 4 | |
Completed |
NCT00574210 -
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
|
Phase 2 | |
Completed |
NCT00420082 -
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
|
Phase 2 | |
Completed |
NCT00443495 -
Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis
|
Phase 1/Phase 2 | |
Completed |
NCT00405899 -
Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections
|
N/A | |
Completed |
NCT03097432 -
Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment
|
N/A |